NCT00043186View on ClinicalTrials.gov

Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density

PHASE2CompletedINTERVENTIONAL
Enrollment

412

Participants

Timeline

Start Date

May 31, 2002

Primary Completion Date

April 30, 2007

Study Completion Date

June 30, 2007

Conditions
Low Bone Mineral Density
Interventions
DRUG

Placebo

Placebo subcutaneous injection

DRUG

Denosumab

Denosumab for subcutaneous injection

DRUG

Alendronate

Alendronate 70 mg tablets

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY